CONSOLIDATED BALANCE SHEETS (USD $)	Mar. 31, 2013		Dec. 31, 2012
Current assets
Cash	$ 288,707		$ 534,046
Prepaid drug product for testing	96,000		195,000
Other current assets	53,924		42,575
Total current assets	438,631		771,621
Other assets
Technology licenses - related party	2,500,374		2,500,374
Less Accumulated Amortization	(968,387)		(928,231)
Intangible Assets, Net (Excluding Goodwill), Total	1,531,987		1,572,143
TOTAL ASSETS	1,970,618		2,343,764
Current liabilities
Accounts payable	71,875		57,000
Accounts payable - related party	0		8,582
Accrued expense	153,541		137,662
Accrued expense - related party	15,000		26,000
Accrued license payments - related party	50,000		100,000
Total current liabilities	290,416		329,244
Long term debt	0		0
TOTAL LIABILITIES	290,416		329,244
Shareholders' Equity
Preferred Stock, $.001 par value 10,000,000 shares authorized, no shares issued and outstanding	0		0
Common Stock, $.001 par value, 200,000,000 shares authorized 62,219,050 shares issued and outstanding as of 3/31/13 and 12/31/12	62,218		62,218
Additional paid in capital	13,296,560		13,321,075
Additional paid in capital for shares to be issued	1,108,711	[1]	762,510	[2]
Accumulated deficit during development stage	(12,787,287)		(12,131,283)
Total shareholders' equity	1,680,202		2,014,520
TOTAL LIABILITIES & SHAREHOLDERS' EQUITY	$ 1,970,618		$ 2,343,764

[1] Represents 3,695,702 shares of common stock

[2] Represents 2,541,700 shares of common stock